Co-Diagnostics, a molecular diagnostics company, will participate in a New York roundtable to discuss the ongoing Ebola outbreak and the technologies needed for better outbreak response. The company is advancing diagnostic tests for the Bundibugyo virus and collaborating on sample-preparation tech to improve decentralized Ebola detection. This involvement highlights Co-Diagnostics' role in supporting rapid diagnostic solutions for emerging global health threats. The company's PCR platform is still under regulatory review and not yet commercially available.
Co-Diagnostics' participation in a global health roundtable on Ebola is noted here alongside Pluang's health sector market snapshot. Of 95 priced health-sector US stocks tradable on Pluang, 56 rose and 25 fell today. Notable movers include TXG at USD 78.08 (+1.93%), RXRX at USD 3.90 (+1.83%), and TWST at USD 170.00 (+1.80%). This data is as of Sep 21, 2026 20:01 WIB.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
